Switch From Remicade to Celltrion’s Biosimilar CT-P13 Safe in IBD, Clinical Trial Concludes

Switch From Remicade to Celltrion’s Biosimilar CT-P13 Safe in IBD, Clinical Trial Concludes
Patients with inflammatory bowel disease (IBD) may safely switch from Remicade (infliximab) to its biosimilar version CT-P13 — sold as Remsima and Inflectra — according to recently published clinical trial results. Since many healthcare systems advocate switching to biosimilars because they’re cheaper, these findings should go a long way in assuring patients and their physicians

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *